BR112012014017A2 - uso terapêutico de conjugados proteína-polímero - Google Patents

uso terapêutico de conjugados proteína-polímero

Info

Publication number
BR112012014017A2
BR112012014017A2 BR112012014017A BR112012014017A BR112012014017A2 BR 112012014017 A2 BR112012014017 A2 BR 112012014017A2 BR 112012014017 A BR112012014017 A BR 112012014017A BR 112012014017 A BR112012014017 A BR 112012014017A BR 112012014017 A2 BR112012014017 A2 BR 112012014017A2
Authority
BR
Brazil
Prior art keywords
protein
therapeutic use
polymer conjugates
polymer
conjugates
Prior art date
Application number
BR112012014017A
Other languages
English (en)
Other versions
BR112012014017B1 (pt
Inventor
Ko-Chung Lin
Rudolf Dr Widmann
Original Assignee
Pharmaessentia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaessentia Corp filed Critical Pharmaessentia Corp
Publication of BR112012014017A2 publication Critical patent/BR112012014017A2/pt
Publication of BR112012014017B1 publication Critical patent/BR112012014017B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Abstract

uso terapêutico de conjugados proteína-polímero. esta invenção relaciona-se ao uso de conjugado proteína-polímeros descrito na especificação para tratar várias doenças, que incluem mielofibrose idiopática, policitemia vera e tromobocitemia essencial.
BR112012014017-5A 2009-12-10 2010-12-09 Uso de conjugados proteína-polímero BR112012014017B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28541109P 2009-12-10 2009-12-10
US61/285,411 2009-12-10
PCT/US2010/059714 WO2011072138A2 (en) 2009-12-10 2010-12-09 Therapeutic use of protein-polymer conjugates

Publications (2)

Publication Number Publication Date
BR112012014017A2 true BR112012014017A2 (pt) 2016-04-12
BR112012014017B1 BR112012014017B1 (pt) 2021-10-26

Family

ID=44146181

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012014017-5A BR112012014017B1 (pt) 2009-12-10 2010-12-09 Uso de conjugados proteína-polímero

Country Status (32)

Country Link
US (1) US8617532B2 (pt)
EP (1) EP2509593B1 (pt)
JP (1) JP5547816B2 (pt)
KR (1) KR101782084B1 (pt)
CN (1) CN102724980B (pt)
AR (1) AR079369A1 (pt)
AU (1) AU2010328067B2 (pt)
BR (1) BR112012014017B1 (pt)
CA (1) CA2782624C (pt)
CL (1) CL2012001503A1 (pt)
CY (1) CY1122901T1 (pt)
DK (1) DK2509593T3 (pt)
EA (1) EA022354B9 (pt)
ES (1) ES2786025T3 (pt)
HK (1) HK1176015A1 (pt)
HR (1) HRP20200678T1 (pt)
HU (1) HUE049051T2 (pt)
IL (1) IL220249A0 (pt)
LT (1) LT2509593T (pt)
MA (1) MA33913B1 (pt)
MX (1) MX337705B (pt)
MY (1) MY169961A (pt)
NZ (1) NZ600528A (pt)
PL (1) PL2509593T3 (pt)
PT (1) PT2509593T (pt)
RS (1) RS60336B1 (pt)
SG (1) SG181084A1 (pt)
SI (1) SI2509593T1 (pt)
TN (1) TN2012000256A1 (pt)
UA (1) UA109646C2 (pt)
WO (1) WO2011072138A2 (pt)
ZA (1) ZA201205056B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ730924A (en) * 2014-11-06 2022-04-29 Pharmaessentia Corp Dosage regimen for pegylated interferon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00239B (me) * 2002-01-18 2011-05-10 Biogen Ma Inc Polimerna jedinjenja polialkilena i njihova upotreba
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
JP5325884B2 (ja) * 2007-09-04 2013-10-23 バイオスティード ジーン エクスプレッション テクノロジー カンパニー リミテッド ポリエチレングリコール化インターフェロンα２ｂならびにその製造方法および使用
GB0908393D0 (en) * 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method

Also Published As

Publication number Publication date
CN102724980A (zh) 2012-10-10
EA201200865A1 (ru) 2012-11-30
HK1176015A1 (en) 2013-07-19
LT2509593T (lt) 2020-05-25
IL220249A0 (en) 2012-07-31
SI2509593T1 (sl) 2020-07-31
MY169961A (en) 2019-06-19
CY1122901T1 (el) 2021-05-05
AR079369A1 (es) 2012-01-18
EA022354B9 (ru) 2016-02-29
DK2509593T3 (da) 2020-05-11
PL2509593T3 (pl) 2020-08-24
US8617532B2 (en) 2013-12-31
AU2010328067B2 (en) 2014-10-02
EP2509593A2 (en) 2012-10-17
ZA201205056B (en) 2013-03-27
WO2011072138A2 (en) 2011-06-16
HRP20200678T1 (hr) 2020-10-02
SG181084A1 (en) 2012-07-30
AU2010328067A1 (en) 2012-07-05
EP2509593B1 (en) 2020-02-12
KR20120110105A (ko) 2012-10-09
PT2509593T (pt) 2020-04-21
MX337705B (es) 2016-03-15
TN2012000256A1 (en) 2013-12-12
KR101782084B1 (ko) 2017-09-26
CA2782624C (en) 2016-11-01
BR112012014017B1 (pt) 2021-10-26
JP5547816B2 (ja) 2014-07-16
RS60336B1 (sr) 2020-07-31
US20110262380A1 (en) 2011-10-27
EP2509593A4 (en) 2016-01-13
MX2012006132A (es) 2012-06-19
CA2782624A1 (en) 2011-06-16
CN102724980B (zh) 2014-10-15
EA022354B1 (ru) 2015-12-30
ES2786025T3 (es) 2020-10-08
UA109646C2 (uk) 2015-09-25
HUE049051T2 (hu) 2020-09-28
CL2012001503A1 (es) 2012-11-09
WO2011072138A9 (en) 2011-10-06
JP2013513611A (ja) 2013-04-22
MA33913B1 (fr) 2013-01-02
NZ600528A (en) 2014-01-31

Similar Documents

Publication Publication Date Title
CR11731A (es) Composiciones y procedimientos para su preparación y uso
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
UY32427A (es) Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
BRPI1011482A2 (pt) composição para uso na redução da transmissão de patógenos humanos
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BR112012026213A2 (pt) pirrolobenzodiazepinas e conjugados das mesmas
CL2011002877A1 (es) Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
GT201200313A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
HN2010000084A (es) Derivados de sulfonamida
AR074777A1 (es) Proteinas de union a antigeno
CR20110091A (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
CR20120490A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
HN2008001292A (es) Anticuerpos contra la ii -22 humana y usos para los mismos
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
CL2008002782A1 (es) Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
UY33124A (es) Agentes y epítopos enlazados a wise
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
ES2408343R1 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
UY33663A (es) Derivados amínicos para el tratamiento de trastornos proliferativos de la piel

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.